22 results
8-K
EX-2.1
CHRS
Coherus Biosciences Inc
22 Jan 24
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in Conference Call Information
8:01am
” or “toxic,” or as a “pollutant” or “contaminant,” under any applicable Environmental Law.
“Health Care Payor” means any governmental, commercial or private
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
27 Oct 23
Regulation FD Disclosure
4:19pm
. Exfoliative dermatitis, including Stevens-Johnson Syndrome (SJS), drug rash with eosinophilia and systemic symptoms (DRESS), and toxic epidermal necrolysis
425
SURF
Surface Oncology, Inc.
16 Jun 23
Business combination disclosure
8:08am
or as hazardous, toxic, radioactive or dangerous or any other term of similar import under any Environmental Law, including but not limited to petroleum
425
SURF
Surface Oncology, Inc.
16 Jun 23
Business combination disclosure
7:09am
, pollutant or contaminant or as hazardous, toxic, radioactive or dangerous or any other term of similar import under any Environmental Law, including
8-K
EX-2.1
bh0so61wotfsuoz0cem
16 Jun 23
Coherus to Acquire Surface Oncology
7:06am
8-K
EX-10.1
13v76v9dv95i1up17frg
11 Jan 19
Entry into a Material Definitive Agreement
4:08pm
10-K
peyrrdcxx2dx2dqqk
23 Mar 15
Annual report
12:00am
424B4
rq33yk0yq 4q3
6 Nov 14
Prospectus supplement with pricing info
12:00am
S-1/A
d5z50uxh
6 Oct 14
IPO registration (amended)
12:00am
DRS/A
qlu2hu27r djb
15 Sep 14
Draft registration statement (amended)
12:00am